This study has revealed how the ZIC2 gene, in collaboration with the ARID1A-BAF complex, plays a crucial role in a process known as epithelial-to-mesenchymal transition (EMT). This process enables ...

The Institute of Cancer Research, London, is seeking a partner to continue the development of ARID1A and other BAF-complex genes as cancer biomarkers for predicting sensitivity to ATRi. More about ...

These cells were used to study how genetic alterations in ARID1A impact the genetic programs of EMT and the function of the ...

Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision ...

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S. FDA. Updated Phase 1b results anticipated in Q2 2025 ...